These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31630548)

  • 1. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
    Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
    Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
    Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
    Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
    Saito H; Tanaka T; Sugahara M; Tanaka S; Fukui K; Wakashima T; Nangaku M
    Lab Invest; 2019 Jul; 99(8):1217-1232. PubMed ID: 30952940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PHD and HSP90 on erythropoietin production in yak (Bos grunniens) renal interstitial fibroblast-like cells under hypoxia.
    Cui Y; Li H; Yu SJ; Afedo SY; Bai XF
    J Mol Histol; 2022 Apr; 53(2):395-411. PubMed ID: 35084636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
    Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enarodustat: First Approval.
    Markham A
    Drugs; 2021 Jan; 81(1):169-174. PubMed ID: 33320297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
    Fujikawa R; Nagao Y; Fujioka M; Akizawa T
    Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
    Sugahara M; Tanaka S; Tanaka T; Saito H; Ishimoto Y; Wakashima T; Ueda M; Fukui K; Shimizu A; Inagi R; Yamauchi T; Kadowaki T; Nangaku M
    J Am Soc Nephrol; 2020 Mar; 31(3):560-577. PubMed ID: 31996409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A.
    Ike T; Doi S; Nakashima A; Sasaki K; Ishiuchi N; Asano T; Masaki T
    Am J Physiol Renal Physiol; 2022 Nov; 323(5):F539-F552. PubMed ID: 36074918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
    J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis.
    Kobayashi H; Davidoff O; Pujari-Palmer S; Drevin M; Haase VH
    Acta Physiol (Oxf); 2022 Aug; 235(4):e13826. PubMed ID: 35491502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
    Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
    Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-PHD inhibitor regulates the function of group2 innate lymphoid cells and polarization of M2 macrophages.
    Nagashima R; Ishikawa H; Kuno Y; Kohda C; Iyoda M
    Sci Rep; 2023 Feb; 13(1):1867. PubMed ID: 36725898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.